SAN
RAFAEL, Calif., Oct. 17,
2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
(NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman
and Chief Executive Officer of BioMarin, will host a conference
call and webcast on Wednesday, November
1, at 4:30 p.m. ET to discuss
third-quarter 2023 financial results and provide a general business
update.
Dial-in Number
U.S. / Canada Dial-in Number: 888-330-3073
International Dial-in Number: 646-960-0683
Conference Call ID: 1816377
U.S. / Canada Replay Dial-in Number: 800-770-2030
International Replay Dial-in Number: 647-362-9199
Playback ID: 1816377
Interested parties may access a live audio webcast of the
conference call via the investor section of the BioMarin
website, https://investors.biomarin.com/. A replay of the call
will be archived on the site for one week following the call.
About BioMarin
Founded in 1997, BioMarin is a global
biotechnology Company dedicated to transforming lives through
genetic discovery. The Company develops and commercializes targeted
therapies that address the root cause of the genetic conditions.
BioMarin's unparalleled research and development capabilities have
resulted in eight transformational commercial therapies for
patients with rare genetic disorders. The Company's distinctive
approach to drug discovery has produced a diverse pipeline of
commercial, clinical, and pre-clinical candidates that address a
significant unmet medical need, have well-understood biology, and
provide an opportunity to be first-to-market or offer a substantial
benefit over existing treatment options. For additional
information, please visit www.biomarin.com.
Contacts:
|
|
Investors
|
Media
|
Traci McCarty
|
Marni Kottle
|
BioMarin
Pharmaceutical Inc.
|
BioMarin
Pharmaceutical Inc.
|
(415)
455-7558
|
(650)
374-2803
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-third-quarter-2023-financial-results-conference-call-and-webcast-on-wednesday-november-1-at-430pm-et-301958470.html
SOURCE BioMarin Pharmaceutical Inc.